gip/glp-1 receptor agonist drugs GLP-1 agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Triple Receptor Agonist The GLP-1 Takeover: Weight Supply Options:6 Month Supply

gip/glp-1 receptor agonist drugs GLP-1 agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Triple Receptor Agonist The GLP-1 Takeover: Weight Supply Options:6 Month Supply

The GLP-1 Takeover: Weight Loss & Addiction

Most commercial plans either don’t cover GLP-1s for weight loss or impose strict access hurdles

Triple Receptor Agonist

Supply Options:6 Month Supply

(The most prescribed GLP-1RA was semaglutide, followed by dulaglutide and tirzepatide.) GLP-1-prescribed groups continued to show lower 1-year mortality, both without and with OSA